Journal
JOURNAL OF CHEMOTHERAPY
Volume 35, Issue 5, Pages 383-396Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1120009X.2022.2121091
Keywords
Remdesivir; COVID-19; mortality; oxygen support; length of stay; time to clinical improvement
Ask authors/readers for more resources
This study conducted a systematic review with meta-analysis and found that Remdesivir did not significantly improve survival in COVID-19 patients receiving standard therapy, but it could significantly reduce the duration of oxygen support.
Remdesivir (RDV) is a broad-spectrum antiviral drug, now approved by Regulatory Agencies for COVID-19 treatment. RDV is associated with improvements in clinical outcomes, but no conclusive studies have shown an effect in reducing mortality. This study aimed to carry out a systematic review with meta-analysis to investigate whether RDV can significantly modify the outcome of COVID-19 patients evaluating its effects on mortality, length of stay, time to clinical improvement and need for oxygen supplementation. No significant improvement in terms of survival in patients treated with standard therapy (ST)+RDV as compared to ST alone (P = 0.24) was found. The duration of oxygen support was significantly lower in patients treated with ST + RDV compared with ST alone (P = 0.03). Further investigations should be planned to assess the real impact of RDV in the management of COVID-19 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available